IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 381 filers reported holding IONIS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $257,000 | -80.4% | 5,421 | -75.6% | 0.00% | -83.3% |
| Q2 2020 | $1,310,000 | -63.7% | 22,220 | -70.9% | 0.01% | -73.9% |
| Q1 2020 | $3,604,000 | +6.6% | 76,228 | +36.2% | 0.02% | +35.3% |
| Q4 2019 | $3,382,000 | +303.1% | 55,976 | +441.3% | 0.02% | +240.0% |
| Q1 2019 | $839,000 | -39.6% | 10,341 | -59.8% | 0.01% | -44.4% |
| Q4 2018 | $1,389,000 | -54.5% | 25,701 | -56.6% | 0.01% | -43.8% |
| Q3 2018 | $3,053,000 | -79.6% | 59,198 | -83.5% | 0.02% | -80.7% |
| Q2 2018 | $14,932,000 | +121.2% | 358,351 | +134.1% | 0.08% | +118.4% |
| Q1 2018 | $6,749,000 | +1140.6% | 153,101 | +1316.3% | 0.04% | +1166.7% |
| Q4 2017 | $544,000 | -0.7% | 10,810 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $548,000 | -78.9% | 10,810 | -78.9% | 0.00% | -81.2% |
| Q2 2017 | $2,601,000 | -91.2% | 51,135 | -93.7% | 0.02% | -93.5% |
| Q3 2016 | $29,595,000 | +50.1% | 807,729 | -4.6% | 0.25% | +47.9% |
| Q2 2016 | $19,719,000 | – | 846,664 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tweedy, Browne Co LLC | 3,510,173 | $159,221,447 | 8.52% |
| Bellevue Group AG | 9,233,700 | $418,840,632 | 6.75% |
| Deep Track Capital, LP | 2,834,069 | $128,553,370 | 4.96% |
| BVF INC/IL | 4,004,613 | $181,649,246 | 4.90% |
| Sicart Associates LLC | 203,132 | $9,214,068 | 3.61% |
| Camber Capital Management LP | 2,250,000 | $102,060 | 3.36% |
| Privium Fund Management B.V. | 228,493 | $10,364,443 | 3.08% |
| Orbimed Advisors | 2,169,500 | $98,408,520 | 2.09% |
| SECTOR GAMMA AS | 165,616 | $7,512,342 | 1.92% |
| TANAKA CAPITAL MANAGEMENT INC | 14,612 | $663 | 1.89% |